

Lendlease is selected to provide Construction Management Services for Pfizer's New Biologics Clinical Manufacturing Facility



(Boston, MA, June 29, 2016) Lendlease was recently selected to provide construction management services for Pfizer's new biologics clinical manufacturing facility in Andover, Massachusetts. On June 16, 2016, Pfizer broke ground for the 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines.

"Lendlease is excited to be a part of the Pfizer team bringing this important facility to reality," stated Scott Tereshak, project executive, Lendlease. "We look forward to adding value by leveraging previous successes with similar types of local biotech facilities."

The new clinical manufacturing facility is designed with 5 independent manufacturing suites to support Pfizer's highly complex and diverse biologics research effort. The facility will:

- Employ flexible design to fully enable Next Generation Manufacturing strategies
- Leverage state-of-the-art single-use bioreactors and disposable process technologies
- Provide clinical manufacturing options with the lowest cost and greatest flexibility for efficiently driving important clinical drugs to patients

"The expansion of Pfizer's presence in Andover will provide state-of-the-art

manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, senior vice president, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”

Lendlease has been operating in the Boston metro area for more than 20 years and within this region completed the first single-use cell culture manufacturing facility in the United States, which received the Facility of the Year Award-Honorable Mention from the ISPE Interphex consortium in 2011. Over the past fifteen years Lendlease has completed in excess of \$1billion of pharmaceutical and manufacturing construction in the New England area.

For additional information, contact:

Nicole Baxevanis

Assistant Director of Marketing

609 919 4129

nicole.baxevanis@lendlease.com

About Lendlease

Lendlease is a leading international property and infrastructure group. Listed on the Australian Securities Exchange and with circa 12,400 (June 2015) employees worldwide, Lendlease’s capabilities span the property value chain.

The Americas region, headquartered in New York, offers core capabilities in development, construction, communities and investment management services. Our expertise covers multiple sectors including arts & culture, aviation, commercial, education, energy, government, healthcare, hotels & resorts, industrial, life science, military communities, mixed-use, multi-site, residential, senior living, telecommunications, transportation and urban regeneration.

We are committed to operating Incident & Injury Free wherever we have a presence, safely creating innovative and sustainable property solutions while forging partnerships and delivering maximum benefits to clients, investors and communities.

www.lendlease.com

